tetano
Editor, Senior Moderator
Nat Rev Microbiol
. 2024 Apr 15.
doi: 10.1038/s41579-024-01036-y. Online ahead of print. COVID-19 drug discovery and treatment options
Jasper Fuk-Woo Chan[SUP] 1 2 3 4 [/SUP], Shuofeng Yuan[SUP] 1 2 3 4 [/SUP], Hin Chu[SUP] 1 2 3 4 [/SUP], Siddharth Sridhar[SUP] 1 2 3 [/SUP], Kwok-Yung Yuen[SUP] 5 6 7 8 [/SUP]
Affiliations
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and mortality, and serious social and economic disruptions worldwide. Unvaccinated or incompletely vaccinated older individuals with underlying diseases are especially prone to severe disease. In patients with non-fatal disease, long COVID affecting multiple body systems may persist for months. Unlike SARS-CoV and Middle East respiratory syndrome coronavirus, which have either been mitigated or remained geographically restricted, SARS-CoV-2 has disseminated globally and is likely to continue circulating in humans with possible emergence of new variants that may render vaccines less effective. Thus, safe, effective and readily available COVID-19 therapeutics are urgently needed. In this Review, we summarize the major drug discovery approaches, preclinical antiviral evaluation models, representative virus-targeting and host-targeting therapeutic options, and key therapeutics currently in clinical use for COVID-19. Preparedness against future coronavirus pandemics relies not only on effective vaccines but also on broad-spectrum antivirals targeting conserved viral components or universal host targets, and new therapeutics that can precisely modulate the immune response during infection.
. 2024 Apr 15.
doi: 10.1038/s41579-024-01036-y. Online ahead of print. COVID-19 drug discovery and treatment options
Jasper Fuk-Woo Chan[SUP] 1 2 3 4 [/SUP], Shuofeng Yuan[SUP] 1 2 3 4 [/SUP], Hin Chu[SUP] 1 2 3 4 [/SUP], Siddharth Sridhar[SUP] 1 2 3 [/SUP], Kwok-Yung Yuen[SUP] 5 6 7 8 [/SUP]
Affiliations
- PMID: 38622352
- DOI: 10.1038/s41579-024-01036-y
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and mortality, and serious social and economic disruptions worldwide. Unvaccinated or incompletely vaccinated older individuals with underlying diseases are especially prone to severe disease. In patients with non-fatal disease, long COVID affecting multiple body systems may persist for months. Unlike SARS-CoV and Middle East respiratory syndrome coronavirus, which have either been mitigated or remained geographically restricted, SARS-CoV-2 has disseminated globally and is likely to continue circulating in humans with possible emergence of new variants that may render vaccines less effective. Thus, safe, effective and readily available COVID-19 therapeutics are urgently needed. In this Review, we summarize the major drug discovery approaches, preclinical antiviral evaluation models, representative virus-targeting and host-targeting therapeutic options, and key therapeutics currently in clinical use for COVID-19. Preparedness against future coronavirus pandemics relies not only on effective vaccines but also on broad-spectrum antivirals targeting conserved viral components or universal host targets, and new therapeutics that can precisely modulate the immune response during infection.